Published On: 6/17/2022
Target RWE Leads Industry Discussion of Fusion Designs and Teaching Advanced Epidemiologic Methods at SER 2022
Target RWE participated in several panels at this year’s Society for Epidemiological Research (SER) annual meeting that will help define the landscape of real-world data collection and analysis for years to come.
When gathering and analyzing large amounts of epidemiological data, researchers are often challenged with how to bring together different datasets in a way that yields meaningful and accurate results. Alexander Breskin, PhD, Senior Director of Statistics at Target RWE, presented research conducted with colleagues at UNC and UCLA during a symposium titled New Epidemiology of Fusion Designs, which introduced novel approaches that challenge conventional thinking about the limitations of how epidemiological studies are currently performed by highlighting principled approaches for combining data from different sources.
In his talk, Fusion Designs for Indirect Treatment Effects, Dr. Breskin demonstrated a new study design and analytic approach that allows researchers to compare treatments that were originally studied in separate clinical trials, thus expanding the range questions can be answered from existing, already collected data. This theoretically grounded approach combines data obtained from multiple sources and appropriately accounts for key factors that differ between their underlying populations, such as factors impacting a patient’s risk of adverse outcomes and adherence to medications.
“Often, studies that attempt to compare treatments used in different populations, such network meta-analyses, fail to account for important differences in the populations that impact the effects of the treatments. Here, we introduce a design and analytic approach, that we refer to as a ‘fusion design’, that is built on a strong theoretical foundation and is shown to provide valid estimates of these so-called ‘indirect treatment comparisons,’” said Dr. Breskin.
Lydia Feinstein, PhD, Senior Director of Epidemiology, is participating in the panel On Teaching Advanced Epidemiologic Methods, an important session that explores the content and tools used to teach epidemiology courses at leading academic institutions. Providing an essential industry perspective, Dr. Feinstein will join with experts in academia and government to weigh in on the importance of preparing students with the skills and thinking necessary to succeed in a competitive and rapidly evolving field.
Dr. Feinstein and Julia Ward, PhD, MPH, Senior Epidemiologist, will also be presenting findings from an important real-world analysis Disparities in Prevalence of Urinary Incontinence among a Nationally Representative Sample of Men, 2005-2016: Findings from the Urologic Diseases in America Project. The study found a high prevalence of urinary incontinence (UI) among a nationally representative population of men in the United States, with a disproportionate burden and a greater daily impact experienced by older men, those of a lower socioeconomic status, and Black men.
“This research contributes to a growing body of disparities research for men across racial and socioeconomic groups,” said Dr. Ward.
Contact us to learn more today!
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
10/09/2024
Advancing RWE: Target RWE's Staging and Clean Room Committee Approaches Set New Benchmark -
08/27/2024
ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour -
08/21/2024
Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement Platform -
08/21/2024
Sequential Nested Trial Emulation Presented by Real-World Evidence Leader Target RWE at ISPE 2024 -
06/12/2024
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions